Skip to content
Hair Pipeline
← Back to the pipeline

ASLAN003

An oral ASLAN candidate at phase 2 in alopecia areata.

Phase 2OralUndisclosed

No public activity in over 18 months

Developed by
ASLAN Pharmaceuticals
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Indications
Alopecia areata
Last public activity
December 2023
Record confidence
Low

Why it matters

Recorded from the registry entry; the mechanism is not disclosed there and this row does not guess at it. One of the few non-JAK oral candidates in alopecia areata.

Development history

  1. Phase 2

    First Phase 2 trial on record: NCT05865041 — Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT05865041Phase 2UNKNOWN

    Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

    ASLAN Pharmaceuticals · n=60 · April 2023

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources